Abstract
The role of angiogenesis in cancer pathophysiology cannot be over emphasized as this process aids tumor metastasis via nourishment of nutrient deprived tumors with oxygen and nutrients. Thus, it is pertinent to inhibit this process via the vascular endothelial growth factor receptor 2 (VEGFR-2). Most available anticancer drugs that targets VEGFR-2 exerts promising angiogenic effects but they bare several adverse effects. Hence, the need to uncover novel compounds from plants with less or no toxicity that have high efficacy targeting angiogenesis. In this present work, in silico docking studies was employed to reveal the potentials of bioactive compounds isolated from Raphia taedigera seed oil against VEGFR-2 using axitinib and sorafenib as control. The crystal structure of VEGFR-2 and the compounds were retrieved from protein database and pubchem servers respectively. The compounds were subjected to drug likeness and ADMET screening using Discovery studio 2016 and AdmetSAR server respectively. The docking between the compounds and VEGFR-2 was carried out with the aid of AutoDock Vina and visualization of the molecular interactions were done using PyMOL, LigPlot+ and Protein–ligand interactions profiler’s server. The results showed that 3-Methoxy-2,3-dimethylundec-1-ene scaled through the drug likeness screening. All the compounds show good binding affinities with 4,4,6a,6b,8a,11,11,14b-Octamethyl-1,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-octadecahydro-2H-picen-3-one having the best binding affinity of -8.9 kcal/mol. The ADMET prediction shows that these compounds are safer than the controls. Conclusively, the in silico study suggests that these compounds could prove to be probable anti-cancer agents but a further study is needed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.